Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2207-2215

  Muldoon, Leslie L ^a,b   Lewin, Seth J ^a   Dósa, Edit ^a   Kraemer, Dale F ^b,c,d,e   Pagel, Michael A ^e   Doolittle, Nancy D ^a   Neuwelt, Edward A ^a,b,e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Department of Cell and Developmental Biology ^*  (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; GADODIAMIDE; IBRITUMOMAB TIUXETAN; METHOTREXATE; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SURVIVAL TIME; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MAGNETIC RESONANCE IMAGING; METHOTREXATE; RANDOM ALLOCATION; RATS; RATS, NUDE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 79954598131     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2923     Document Type: Article

References (39)

1. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281-8. (Pubitemid 46622031)
2. Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep 2009;11:73-80.
3. Swinnen LJ. Primary central nervous system lymphoma: recent progress, many remaining questions. Curr Opin Oncol 2009;21:393-6.
4. Abrey LE, De Angelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-63. (Pubitemid 28108717)
5. Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience with 149 patients. J Clin Oncol 2009;27:3503-9.
6. Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-71. (Pubitemid 28108718)
7. De Angelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-8. (Pubitemid 36025280)
8. Gavrilovic IT, Hormigo A, Yahalom J, De Angelis LM, Abrey LE. Longterm follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24:4570-4. (Pubitemid 46630953)
9. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-95. (Pubitemid 46594018)
10. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865-70. (Pubitemid 46630733)
11. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDSrelated primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003;21:4483-8. (Pubitemid 46594017)
12. Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus 2006;21:E1.
13. Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma 2006; Suppl 1: S7-13.
14. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005;23:6421-8. (Pubitemid 46218853)
15. Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW, Lacy CA, et al. Potential of immunochemotherapy and radioimmunotherapy in relapsed primary CNS lymphoma. Leukemia Lymphoma 2007;48:1712-20. (Pubitemid 47386706)
16. Enting RH, Demopoulos A, De Angelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-3. (Pubitemid 39297656)
17. Ney DE, Abrey LE. Maintenance therapy for central nervous system lymphoma with rituximab. Leuk Lymphoma 2009;50:1548-51.
18. Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab. Onkologie 2003;26:351-4.
19. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350-6. (Pubitemid 46706881)
20. Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004;101:139-45. (Pubitemid 38812433)
21. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro-Oncol 2009;11:423-9.
22. Neuwelt EA, Barnett P, McCormick CI, Remsen LG, Kroll RA, Sexton G. Differential permeability of a human brain tumor xenograft in the nude rat: the impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res 1998;4:1549-56.
23. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 2004;309:594-9. (Pubitemid 38542612)
24. Remsen LG, Trail PA, Hellström I, Hellström KE, Neuwelt EA. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 2000;46:704-9. (Pubitemid 30146158)
25. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, et al. Safety and efficacy of a multi-center study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of malignant brain tumors. Cancer 2000;88:637-47. (Pubitemid 30056941)
26. Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Brown RD, Kraemer DF, et al. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat central nervous system lymphoma model. Neuro-Oncol 2009;11:503-13.
27. Soussain C, Muldoon LL, Varallyay C, Jahnke K, De Paula L, Neuwelt EA. Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma. Clin Cancer Res 2007;13:2504-11. (Pubitemid 46698603)
28. Magrath IT, Freeman CB, Pizzo P, Gadek J, Jaffe E, Santaella M, et al. Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface markers. J Natl Cancer Inst 1980;64:477-83. (Pubitemid 10127261)
29. Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG, Neuwelt EA. Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia 2009;11:187-95.
30. Remsen LG, Pagel MA, McCormick CI, Fiamengo S, Sexton G, Neuwelt EA. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain xenografts. Anesth Analg 1999;88:559-67. (Pubitemid 29109022)
31. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63. (Pubitemid 34525730)
32. Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, et al. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res 2009;15:1989-97.
33. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, et al. Cognitive outcomes and long-term follow-up after enhanced chemotherapy delivery for primary central nervous system lymphomas. Neurosurgery 2000;46:51-61. (Pubitemid 30030265)
34. Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA. An exploratory study of ferumoxtran-10 nanoparticles as a blood brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. AJNR: Am J Neuroradiol 2005;26:2290-300.
35. Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730-5. (Pubitemid 350086474)
36. Mineo J-F, Scheffer A, Karkoutly C, Nouvel L, Kerdraon O, Trauet J, et al. Using Human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci 2008;49:4738-45.
37. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466-8. (Pubitemid 36077565)
38. Flinn IW, Ambinder RF. AIDS primary central nervous system lymphoma. Curr Opin Oncol 1996;8:373-6. (Pubitemid 26367427)
39. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thoughts for the best use? Crit Rev Oncol Hematol 2007;62:43-52. (Pubitemid 46330791)